Impact of drug conjugation on pharmacokinetics and tissue distribution of Anti-STEAP1 antibody-drug conjugates in rats

Bioconjugate Chemistry

Volumn 22, Issue 10, 2011, Pages 1994-2004

  Boswell, C Andrew ^a   Mundo, Eduardo E ^a   Zhang, Crystal ^a   Bumbaca, Daniela ^a   Valle, Nicole R ^a   Kozak, Katherine R ^a   Fourie, Aimee ^a   Chuh, Josefa ^a   Koppada, Neelima ^a   Saad, Ola ^a   Gill, Herman ^a   Shen, Ben Quan ^a   Rubinfeld, Bonnee ^a   Tibbitts, Jay ^a   Kaur, Surinder ^a   Theil, Frank Peter ^a   Fielder, Paul J ^a   Khawli, Leslie A ^a   Lin, Kedan ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; ANTIGENS; CHEMICAL STABILITY; DRUG DOSAGE; RATS; SULFUR COMPOUNDS; TUMORS;

ANTIBODY-DRUG CONJUGATES; CHEMOTHERAPEUTIC DRUGS; CYTOTOXIC; DRUG-CONJUGATES; ENZYME LINKED IMMUNOSORBENT ASSAY; GENERAL CHEMICALS; PHARMACOKINETIC PROFILES; TISSUE DISTRIBUTIONS; TRANSMEMBRANES; TUMOR ANTIGEN;

PHARMACOKINETICS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID INDIUM 111; ANTINEOPLASTIC AGENT; CYSTEINE; DISULFIDE; MONOMETHYLAURISTATIN E; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 1 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUGATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

RATTUS;

EID: 80054794058     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200212a     Document Type: Article

References (49)

1. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010) Cancer statistics, 2010 CA Cancer J. Clin. 60, 277-300
2. Hricak, H., Choyke, P. L., Eberhardt, S. C., Leibel, S. A., and Scardino, P. T. (2007) Imaging prostate cancer: a multidisciplinary perspective Radiology 243, 28-53 (Pubitemid 46579693)
3. Ravizzini, G., Turkbey, B., Kurdziel, K., and Choyke, P. L. (2009) New horizons in prostate cancer imaging Eur. J. Radiol. 70, 212-26
4. Denmeade, S. R. and Isaacs, J. T. (2002) A history of prostate cancer treatment Nat. Rev. Cancer 2, 389-96 (Pubitemid 37328952)
5. Lin, G. A., Aaronson, D. S., Knight, S. J., Carroll, P. R., and Dudley, R. A. (2009) Patient decision aids for prostate cancer treatment: a systematic review of the literature CA Cancer J. Clin. 59, 379-90
6. Rosenthal, S. A. and Sandler, H. M. (2010) Treatment strategies for high-risk locally advanced prostate cancer Nat. Rev. Urol. 7, 31-8
7. Shepard, D. R. and Raghavan, D. (2009) Innovations in the systemic therapy of prostate cancer Nat. Rev. Clin. Oncol. 7, 13-21
8. Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., Jakobovits, A., Saffran, D. C., and Afar, D. E. (1999) STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors Proc. Natl. Acad. Sci. U. S. A. 96, 14523-8 (Pubitemid 30000683)
9. Challita-Eid, P. M., Morrison, K., Etessami, S., An, Z., Morrison, K. J., Perez-Villar, J. J., Raitano, A. B., Jia, X. C., Gudas, J. M., Kanner, S. B., and Jakobovits, A. (2007) Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo Cancer Res. 67, 5798-805 (Pubitemid 46985013)
10. Ohgami, R. S., Campagna, D. R., McDonald, A., and Fleming, M. D. (2006) The Steap proteins are metalloreductases Blood 108, 1388-94 (Pubitemid 44232042)
11. Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M., Law, C. L., Senter, P. D., and Benjamin, D. R. (2009) The pharmacologic basis for antibody-auristatin conjugate activity J. Pharmacol. Exp. Ther. 330, 932-8
12. Carter, P. J. and Senter, P. D. (2008) Antibody-drug conjugates for cancer therapy Cancer J. 14, 154-69
13. Chen, Y., Clark, S., Wong, T., Dennis, M. S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H., Gogineni, A., Ross, S., Polakis, P., and Mallet, W. (2007) Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models Cancer Res. 67, 4924-32 (Pubitemid 46910200)
14. Ducry, L. and Stump, B. (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjugate Chem. 21, 5-13
15. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-32
16. Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V., Lutz, R. J., Wong, W. L., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68, 9280-90
17. Senter, P. D. (2009) Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13, 235-44
18. Teicher, B. A. (2009) Antibody-drug conjugate targets Curr. Cancer Drug Targets 9, 982-1004
19. Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A., Jack, A., Junutula, J. R., Koeppen, H., Lau, J., McBride, J., Rawstron, A., Shi, X., Yu, N., Yu, S. F., Yue, P., Zheng, B., Ebens, A., and Polson, A. G. (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 114, 2721-9
20. Mandler, R., Kobayashi, H., Hinson, E. R., Brechbiel, M. W., and Waldmann, T. A. (2004) Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity Cancer Res. 64, 1460-7 (Pubitemid 38235617)
21. Bai, R. L., Pettit, G. R., and Hamel, E. (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites J. Biol. Chem. 265, 17141-9
22. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-84 (Pubitemid 36791396)
23. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C. L., Doronina, S. O., Siegall, C. B., Senter, P. D., and Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102, 1458-65 (Pubitemid 36988057)
24. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-70 (Pubitemid 39383058)
25. McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., and Carter, P. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel. 19, 299-307 (Pubitemid 43999640)
26. McKenna, T., Batson, J., Ross, S., Polakis, P., and Rubinfeld, B. (2007) Armed antibodies targeted to STEAP1 inhibit growth of human prostate xenografts in vivo AACR Meeting Abstracts 2007, 4468
27. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M. (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions Anal. Biochem. 142, 68-78
28. Lewis, M. R., Kao, J. Y., Anderson, A. L., Shively, J. E., and Raubitschek, A. (2001) An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA Bioconjugate Chem. 12, 320-4 (Pubitemid 32235486)
29. Davies, B. and Morris, T. (1993) Physiological parameters in laboratory animals and humans Pharm. Res. 10, 1093-5 (Pubitemid 23211439)
30. Lin, K., Lou, T., Ferl, G., Leipold, D., Graham, R., Kozak, K. R., Polakis, P., Tibbits, J., and Theil, F. P. (2009) Cross-species pharmacokinetic characterization of antibody drug conjugate TenB2-vc-E to understand target biology AAPS Meeting Abstracts 2009
31. Stephan, J. P., Chan, P., Lee, C., Nelson, C., Elliott, J. M., Bechtel, C., Raab, H., Xie, D., Akutagawa, J., Baudys, J., Saad, O., Prabhu, S., Wong, W. L., Vandlen, R., Jacobson, F., and Ebens, A. (2008) Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination Bioconjugate Chem. 19, 1673-83
32. Austin, C. D., Wen, X., Gazzard, L., Nelson, C., Scheller, R. H., and Scales, S. J. (2005) Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates Proc. Natl. Acad. Sci. U. S. A. 102, 17987-92 (Pubitemid 41798489)
33. Doronina, S. O., Bovee, T. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Morris-Tilden, C. A., and Senter, P. D. (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate Bioconjugate Chem. 19, 1960-3
34. Perera, R. M., Zoncu, R., Johns, T. G., Pypaert, M., Lee, F. T., Mellman, I., Old, L. J., Toomre, D. K., and Scott, A. M. (2007) Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody Neoplasia 9, 1099-110 (Pubitemid 350255358)
35. Zheng, B., Fuji, R. N., Elkins, K., Yu, S. F., Fuh, F. K., Chuh, J., Tan, C., Hongo, J. A., Raab, H., Kozak, K. R., Williams, M., McDorman, E., Eaton, D., Ebens, A., and Polson, A. G. (2009) In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates Mol. Cancer Ther. 8, 2937-46
36. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-65 (Pubitemid 351431408)
37. Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., Mai, E., Lewis Phillips, G. D., Hiraragi, H., Fuji, R. N., Tibbitts, J., Vandlen, R., Spencer, S. D., Scheller, R. H., Polakis, P., and Sliwkowski, M. X. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16, 4769-78
38. Xie, H., Audette, C., Hoffee, M., Lambert, J. M., and Blattler, W. A. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice J Pharmacol. Exp. Ther. 308, 1073-82 (Pubitemid 38263984)
39. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo Cancer Res. 55, 5714s-5720s
40. Boswell, C. A., Ferl, G. Z., Mundo, E. E., Bumbaca, D., Schweiger, M. G., Theil, F. P., Fielder, P. J., and Khawli, L. A. (2011) Effects of Anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow PLoS One 6, e17874
41. Boswell, C. A., Ferl, G. Z., Mundo, E. E., Schweiger, M. G., Marik, J., Reich, M. P., Theil, F. P., Fielder, P. J., and Khawli, L. A. (2010) Development and evaluation of a novel method for preclinical measurement of tissue vascular volume Mol. Pharm. 7, 1848-1857
42. Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F. P., Fielder, P. J., and Khawli, L. A. (2010) Effects of charge on antibody tissue distribution and pharmacokinetics Bioconjugate Chem. 21, 2153-2362
43. Al-Ejeh, F., Darby, J. M., Thierry, B., and Brown, M. P. (2009) A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution Nucl. Med. Biol. 36, 395-402
44. 125I-labeled antiTac single-chain Fv recombinant immunotoxin J. Nucl. Med. 41, 755-62 (Pubitemid 30207755)
45. Boswell, C. A. and Brechbiel, M. W. (2007) Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view Nucl. Med. Biol. 34, 757-78 (Pubitemid 47503817)
46. Boswell, C. A., Sun, X., Niu, W., Weisman, G. R., Wong, E. H., Rheingold, A. L., and Anderson, C. J. (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes J. Med. Chem. 47, 1465-74 (Pubitemid 38327472)
47. Bryan, J. N., Jia, F., Mohsin, H., Sivaguru, G., Miller, W. H., Anderson, C. J., Henry, C. J., and Lewis, M. R. (2005) Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer Nucl. Med. Biol. 32, 851-8 (Pubitemid 41509196)
48. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates Bioconjugate Chem. 5, 565-76
49. DeLano, W. L. (2008) The PyMOL Molecular Graphics System, DeLano Scientific LLC, Palo Alto, CA, USA, http://www.pymol.org.